LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Cutting through the politics: presidential candidates' healthcare platforms and impact on health benefits.

    Howell, Peyton

    American health & drug benefits

    2014  Volume 1, Issue 8, Page(s) 8–14

    Abstract: Healthcare reform is one of the top issues for the presidential elections this year, and both candidates have proposed a wide range of health policy changes that could be the most important changes to the delivery of care in the country since the ... ...

    Abstract Healthcare reform is one of the top issues for the presidential elections this year, and both candidates have proposed a wide range of health policy changes that could be the most important changes to the delivery of care in the country since the creation of Medicare and Medicaid in the 1960s. This article provides a summary analysis of the healthcare platforms of the presidential candidates. Specifically, the major components of their published health plan proposals are broken out and compared using the language and descriptions from the candidates. The article also highlights several healthcare reform proposals from health advocacy organizations, as well as insights from medical directors and pharmacy directors across more than 50 major managed care health plans. By framing the issues, the article provides a basis for consideration of more detail as healthcare reform recommendations are developed by Congress in 2009.
    Language English
    Publishing date 2014-07-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2853721-X
    ISSN 1942-2970 ; 1942-2962
    ISSN (online) 1942-2970
    ISSN 1942-2962
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Payer perspectives on healthcare reform.

    Howell, Peyton / Reeder, Gene / Regan, Timothy S

    American health & drug benefits

    2014  Volume 2, Issue 4, Page(s) 181–183

    Language English
    Publishing date 2014-07-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2853721-X
    ISSN 1942-2970 ; 1942-2962
    ISSN (online) 1942-2970
    ISSN 1942-2962
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.

    Johnson, Philip E / Dahlman, George / Eng, Kirby / Garg, Rekha / Gottlieb, Scott / Hoffman, James M / Howell, Peyton / Jahanzeb, Mohammad / Johnson, Shirley / Mackler, Emily / Rubino, Mark / Sarokhan, Brenda / Marc Stewart, F / Tyler, Tim / Vose, Julie M / Weinstein, Sharon / Li, Edward C / Demartino, Jessica

    Journal of the National Comprehensive Cancer Network : JNCCN

    2010  Volume 8 Suppl 7, Page(s) S7–S27

    Abstract: REMS are a particularly important issue for oncology and the National Comprehensive Cancer Network (NCCN). A disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders. REMS policies and processes within ... ...

    Abstract REMS are a particularly important issue for oncology and the National Comprehensive Cancer Network (NCCN). A disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders. REMS policies and processes within oncology may act as a model for other clinical areas. A breadth of experience and access to a wide knowledge base exists within oncology that will ensure appropriate development and consideration of the practical implications of REMS. NCCN is uniquely positioned to assume a leadership role in this process given its status as the arbiter of high-quality cancer care based on its world-leading institutions and clinicians. Notwithstanding the potential benefits, the successful design, implementation, and analysis of the FDA's recent requirement for REMS for some high-risk drugs and biologics will present significant challenges for stakeholders, including patients, providers, cancer centers, manufacturers, payors, health information technology vendors, and regulatory agencies. To provide guidance to these stakeholders regarding REMS challenges, the NCCN assembled a work group comprised of thought leaders from NCCN Member Institutions and other outside experts. The Work Group identified challenges across the REMS spectrum, including the areas of standardization, development and assessment of REMS programs, medication guides, provider knowledge and impact on prescribing, provider burden and compensation, and incorporation of REMS into clinical practice.
    MeSH term(s) Advisory Committees/organization & administration ; Antineoplastic Agents/therapeutic use ; Biological Products/therapeutic use ; Drug Industry/standards ; Drug Industry/trends ; Drug Labeling/standards ; Drug Labeling/trends ; Drug Monitoring/standards ; Drug Monitoring/trends ; Drug Therapy/methods ; Drug Therapy/standards ; Drug Therapy/trends ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Drugs, Investigational/therapeutic use ; Expert Testimony ; Health Care Surveys ; Health Literacy ; Health Personnel/economics ; Humans ; Interdisciplinary Communication ; Medical Oncology/methods ; Medical Oncology/standards ; Medical Oncology/trends ; Off-Label Use/standards ; Reimbursement Mechanisms ; Risk Assessment/methods ; Risk Assessment/standards ; Risk Assessment/trends ; Safety Management/methods ; Safety Management/standards ; Safety Management/trends ; United States ; United States Food and Drug Administration/legislation & jurisprudence
    Chemical Substances Antineoplastic Agents ; Biological Products ; Drugs, Investigational
    Language English
    Publishing date 2010-10-08
    Publishing country United States
    Document type Guideline ; Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1405
    ISSN 1540-1405
    DOI 10.6004/jnccn.2010.0135
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top